Core Insights - The article emphasizes the importance of earnings estimate revisions in predicting investor reactions and stock price performance [1] Sales Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $168.14 million, reflecting a +9.6% change from the previous year [2] - The consensus estimate for 'Sales- Total Medical Sales' is $429.74 million, indicating a +10.4% change year over year [6] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $25.06 million, showing a -7.9% change from the prior year [5] - 'Sales- Non-Medical' is projected at $8.52 million, indicating a -22.1% change from the previous year [9] - 'Sales- Medical Sales- Cardio & Vascular' is expected to reach $236.43 million, reflecting a +13.4% change year over year [10] Earnings Estimates - The upcoming report from Integer (ITGR) is anticipated to show quarterly earnings of $1.24 per share, which is an increase of 8.8% compared to the same period last year [7] - Analysts forecast revenues of $438.15 million for Integer, representing a 9.5% increase year over year [7] Market Performance - Integer shares have experienced an +8.5% change over the past month, contrasting with a -0.3% move of the Zacks S&P 500 composite [7] - Integer holds a Zacks Rank 4 (Sell), suggesting it is expected to underperform the overall market in the near future [7] Analyst Consensus - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating analysts' collective reassessment of their initial forecasts [3] - The article suggests that analyzing key metrics projected by analysts can provide a more comprehensive view of the company's performance [8]

Over the last four quarters, the company has surpassed consensus EPS estimates four times. Integer shares have added about 25.7% since the beginning of the year versus the S&P 500's gain of 13.8%. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Investors should be min ...

EXHIBIT 99.1 Integer Holdings Corporation Reports Second Quarter 2024 Results ~ Continued strong performance with 2Q24 financial results ~ ~ Raising full year 2024 profit outlook ~ PLANO, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended June 28, 2024. Second Quarter 2024 Highlights (compared to Second Quarter 2023, except as noted) "Integer delivered another strong quarter with 9% sales growth and a 20% increase in adjusted ...

Investor Relations: Media Relations: Andrew Senn Kelly Butler andrew.senn@integer.net kelly.butler@integer.net 763.951.8312 469.731.6617 The Notes are convertible at a conversion rate of 11.4681 shares of common stock per $1,000 principal amount of Notes, which is equivalent to a conversion price of approximately $87.20 per share of common stock. None of the Company, its Board of Directors or its employees has made or is making any representation or recommendation to any holder as to whether to exercise or ...

Group 1 - Integer Holdings Corporation has notified holders of its 2.125% Convertible Senior Notes due 2028 that the Notes are convertible from July 1, 2024, to September 30, 2024, at the option of the holders [1][3] - The conversion rate is set at 11.4681 shares of common stock per $1,000 principal amount of Notes, translating to a conversion price of approximately $87.20 per share [4] - The conversion became available as the last reported sale price of the Company's common stock exceeded 130% of the conversion price for at least 20 trading days within a 30-day period ending June 30, 2024 [3] Group 2 - The Company has amended its existing credit agreement to increase its maximum borrowing capacity under the revolving credit facility by $300 million, raising it from $500 million to $800 million [7] - The Chief Financial Officer stated that the Company aims to enhance its liquidity sources to support long-term strategic objectives while maintaining a debt leverage target of 2.5 to 3.5 [8] - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving various markets including cardiac rhythm management and neuromodulation [8]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

PLANO, Texas, June 27, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for second quarter 2024 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, July 25, 2024. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Date: Thursday, July 25, 2024 Time: 8 a.m ...

PLANO, Texas, June 27, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for second quarter 2024 at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, July 25, 2024. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call. Conference call details: Date: Thursday, ...

Core Viewpoint - Integer Holdings Corporation (ITGR) is experiencing growth driven by its research and product development activities, with a strong performance in Q1 2024 contributing to optimism in the MedTech sector, although regulatory challenges and reliance on third-party suppliers pose risks [1][3][17]. Company Performance - Integer Holdings reported robust first-quarter 2024 results, showing year-over-year growth in both top-line and bottom-line metrics, particularly in its Medical segment due to strong product line performance [3][7]. - The company has a market capitalization of $3.93 billion and projects a 12.8% growth rate over the next five years, maintaining strong performance and surpassing Zacks Consensus Estimates in the last four quarters with an average earnings surprise of 10.4% [7][8]. Research and Development - The company is focused on internal technology and capability development to provide differentiated solutions, while also collaborating with external research institutions for unique technology projects [2][8]. - ITGR is enhancing existing products and expanding their applications, particularly in the Cardio & Vascular, Neuromodulation, and Non-Medical Electrochem markets [9][8]. Market Position - Integer Holdings has a solid foothold in the broader MedTech space, particularly in cardiac, neuromodulation, orthopedics, vascular, and advanced surgical markets, serving large multinational original equipment manufacturers [17][1]. - The company is undertaking strategic initiatives to maintain its leadership in the cardiac rhythm management market [9]. Regulatory Environment - The healthcare industry regulations, including the European Medical Device Regulation, impose compliance costs that could affect revenue and operational results [4][10]. - Integer Holdings' product lines are subject to various health and safety regulations at multiple levels, which may lead to higher-than-anticipated costs [10][4]. Estimate Trends - The Zacks Consensus Estimate for Integer Holdings' second-quarter 2024 revenues is projected at $437.3 million, reflecting a 9.3% increase from the previous year [20]. - However, there has been a negative estimate revision trend for 2024, with earnings estimates moving down by 1.3% to $5.27 per share over the past 90 days [5].

PLANO, Texas, June 06, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced participation at the 2024 Truist Securities MedTech Conference, to be held June 17 – 18, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present as part of a fireside chat on Tuesday, June 18, at 1:55 p.m. ET. A live webcast of the presentation will be accessible un ...